Irati Garmendia

434 citations
12 papers · 219 indexed · h-index 8
Topics
Cancer-related gene regulation (4 papers)Lung Cancer Treatments and Mutations (3 papers)PI3K/AKT/mTOR signaling in cancer (3 papers)

In The Last Decade

Irati Garmendia

9 papers receiving 219 citations

Peers

Irati Garmendia
Comparison fields: 5 of 41
  • Molecular Biology 112
  • Oncology 98
  • Cancer Research 54
  • Pulmonary and Respiratory Medicine 44
  • Immunology 42
Replace Chengqin Wang with:
Chengqin Wang China
Shinya Kidogami Japan
Junyu Tan China
Chung‐Chi Hsu Taiwan
Ina Menzl United States
Hsuan-Yu Peng Taiwan
Anja Brouwer Belgium
Rachel A. Woolaver United States
Natascha Santacroce Switzerland
Zhuming Lu China
Irati Garmendia relative to Chengqin Wang China Chengqin Wang's profile →
Citations per field
00.5×1.5×
Chengqin Wang · 1×
Citations per year

Countries citing papers authored by Irati Garmendia

Since Specialization
Citations

This map shows the geographic impact of Irati Garmendia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irati Garmendia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irati Garmendia more than expected).

Fields of papers citing papers by Irati Garmendia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irati Garmendia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irati Garmendia. The network helps show where Irati Garmendia may publish in the future.

Co-authorship network of co-authors of Irati Garmendia

This figure shows the co-authorship network connecting the top 25 collaborators of Irati Garmendia. A scholar is included among the top collaborators of Irati Garmendia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irati Garmendia. Irati Garmendia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
#WorkIndexed citations
1 32
2 3
3 17
4 51
5 48
6 11
7 17
8 31
9 0
10 0
11 0
12 9

About Irati Garmendia

Irati Garmendia is a scholar working on Immunology and Allergy, Oncology and Pulmonary and Respiratory Medicine, having authored 12 papers that have together received 219 indexed citations. Recurring topics across this work include Cancer-related gene regulation (4 papers), Lung Cancer Treatments and Mutations (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). The work is most often cited by research in Oncology (98 citations), Cancer Research (54 citations) and Otorhinolaryngology (11 citations). Irati Garmendia has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Luis M. Montuenga, Alfonso Calvo, Jackeline Agorreta, Esther Redín, Juana García-Pedrero, Juan P. Rodrigo, Eva Allonca, Rocío Granda‐Díaz, Rubén Pı́o and Fernando López. Their work appears in journals such as Cancer Research, International Journal of Molecular Sciences and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026